Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹7,974 Cr
Revenue (TTM)
₹1,837 Cr
Net Profit (TTM)
₹327 Cr
ROE
36.1 %
ROCE
46.2 %
P/E Ratio
24.4
P/B Ratio
10.6
Industry P/E
28.7
EV/EBITDA
15.1
Div. Yield
3.6 %
Debt to Equity
0
Book Value
₹325.3
EPS
₹150.7
Face value
10
Shares outstanding
23,030,622
CFO
₹4,017.10 Cr
EBITDA
₹5,975.30 Cr
Net Profit
₹4,467.40 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sanofi India
| -15.3 | -14.0 | -15.9 | -37.9 | -12.4 | -14.0 | -0.8 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sanofi India
| -32.9 | -24.6 | 37.8 | -25.8 | -4.6 | 18.7 | 10.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sanofi India
|
3,460.8 | 7,974.5 | 1,837.4 | 326.7 | 24.7 | 45.3 | 24.4 | 10.6 |
| 3,056.6 | 38,176.6 | 5,201.6 | 1,014.6 | 22.9 | 25 | 37.6 | 8.3 | |
| 8,483.5 | 21,239.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 105.7 | 25.5 | |
| 1,648.2 | 12,536.2 | 2,089.5 | 622.0 | 31.3 | 20.4 | 20.4 | 3.8 | |
| 1,631.1 | 9,972.2 | 1,196.4 | 149.4 | -- | 27.5 | 66.7 | 14.2 | |
| 1,308.1 | 18,156.7 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.1 | 5.0 | |
| 2,118.0 | 33,968.6 | 4,193.0 | 753.8 | 22.7 | 20.8 | 45.1 | 8.5 | |
| 4,818.0 | 22,063.4 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.8 | 5.5 | |
| 4,939.8 | 8,194.5 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.9 | 11.8 | |
| 907.1 | 8,342.6 | 4,725.6 | 528.7 | 14.9 | 20.7 | 16.3 | 2.8 |
2 min read•By Value Research
4 min read•By Anindya Bera
4 min read•By Research Desk
3 min read•By Research Desk
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis,... infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH. Read more
Incorporated
1956
Chairman
Aditya Narayan
Managing Director
Deepak Arora
Group
Sanofi India - MNC
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Sanofi India Ltd is ₹3,460.80 (NSE) and ₹3,462.55 (BSE) as of 18-Mar-2026 IST. Sanofi India Ltd has given a return of -12.42% in the last 3 years.
The P/E ratio of Sanofi India Ltd is 24.41 times as on 18-Mar-2026, a 15 discount to its peers’ median range of 28.70 times.
The P/B ratio of Sanofi India Ltd is 10.64 times as on 18-Mar-2026, a 133 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
34.06
|
17.80
|
|
2023
|
30.78
|
19.59
|
|
2022
|
21.68
|
11.09
|
|
2021
|
19.22
|
8.38
|
|
2020
|
40.06
|
9.26
|
The 52-week high and low of Sanofi India Ltd are Rs 6,717.00 and Rs 3,415.00 as of 19-Mar-2026.
Sanofi India Ltd has a market capitalisation of ₹ 7,974 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sanofi India Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹12.50
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.